Clinical Trial Update: Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating the combination of chemotherapy and erlotinib for non-small cell lung cancer with low-abundance EGFR mutations has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: TERMINATED